Last reviewed · How we verify
BNT162b2 OMI (bnt162b2-omi)
BNT162b2 OMI, developed by Pfizer Inc., is a marketed drug for COVID-19 prevention and treatment. It has a significant revenue of 63.6B. The drug has undergone 11 trials and has 2 publications. BNT162b2 OMI's mechanism is not specified. It has clinical differentiation in its key indications. The commercial significance of the drug is substantial. There are no pipeline developments mentioned.
At a glance
| Generic name | bnt162b2-omi |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- COVID-19 prevention
- COVID-19 treatment
Common side effects
Drug interactions
- Warfarin
- Aspirin
- P2Y12 inhibitors
- Anticoagulants
- Corticosteroids
- Live vaccines
- Interferons
- Immunosuppressants
Key clinical trials
- Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (PHASE1)
- Korea Comirnaty Post-marketing Surveillance
- To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. (PHASE3)
- A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals (PHASE2, PHASE3)
- A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults (PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (PHASE2)
- Secondary Databased Post-marketing Surveillance Study of BNT162b2
- A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b2 OMI CI brief — competitive landscape report
- BNT162b2 OMI updates RSS · CI watch RSS
- Pfizer portfolio CI